Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Celgene Corp. (CELG) Broke Out To A New High After Q3 Profit Beat24 Oct 2014, 4:49 amCelgene Corp. (CELG) reported third quarter adjusted EPS of $0.97 Thursday morning, up from $0.78 in the previous year. Analysts expected EPS of $0.95. The company also raised its full year adjusted EPS guidance to a range of $3.65 to $3.70, from the prior forecast of $3.60 to $3.65. The consensus estimate is for EPS of $3.67.
Jim Cramer's Top Stock Picks: CELG FTK BA JAH AVT24 Oct 2014, 4:28 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Thursday's Mad Money on CNBC: CELG data by YCharts Celgene : Cramer said this biotech had a lot of positive things to say when itareleased earnings and remains one of his favorites in the group. FTK data by ...
GT Advanced Technologies Reaches Agreement with Apple; Nokia Corporation Soars on Q3 Earnings23 Oct 2014, 10:00 pmACCESSWIRE / October 24, 2014 / Topping Q3 Earnings pushes Nokia Corporation (NYSE: NOK) shares higher on Thursday with the stock closing up %.
Stock picks: 15 trades in 67 seconds23 Oct 2014, 5:04 pmThe "Fast Money" traders share what stocks they're watching.
Celgene Beats Q3 Earnings Estimates on High Revlimid Sales23 Oct 2014, 9:50 amCelgene (CELG) reported higher than expected earnings in the quarter.
Celgene beats Street 3Q forecasts23 Oct 2014, 5:54 amThe Summit, New Jersey-based company said it had profit of 61 cents per share. Earnings, adjusted for one-time gains and costs, were 97 cents per share. The results surpassed Wall Street expectations. ...
Celgene Reports Third Quarter 2014 Operating and Financial Results23 Oct 2014, 5:30 amCelgene Corporation reported net product sales of $1,957 million for the third quarter of 2014, a 19 percent increase from the same period in 2013. Third quarter total revenue increased 18 percent to $1,982 million compared to $1,674 million in the third quarter of 2013.
Pre-Market Earnings Report for October 23, 2014 : CMCSA, UNP, MMM, CELG, LLY, OXY, CAT, GM, ALXN, PCP, RTN, POT22 Oct 2014, 2:16 pmPre-Market Earnings Report for October 23, 2014 : CMCSA, UNP, MMM, CELG, LLY, OXY, CAT, GM, ALXN, PCP, RTN, POT
Celgene (CELG) Q3 Earnings to Be Overrun by Expenses?21 Oct 2014, 1:50 pmCelgene (CELG) is scheduled to report third-quarter 2014 results on Oct 23.
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By ...8 Oct 2014, 7:44 amCHICAGO, Oct. 8, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XOM, CELG, VZ, ICPT and LMT. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You...